Barriers to medical provider support for prescription naloxone as overdose antidote for lay responders

Substance Use and Misuse

Volumn 48, Issue 7, 2013, Pages 558-567

  Green, Traci C ^a   Bowman, Sarah E ^b   Zaller, Nickolas D ^c   Ray, Madeline ^b   Case, Patricia ^d   Heimer, Robert ^e  

^a BROWN UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

^c MIRIAM HOSPITAL   (United States)

^d Fenway Community Health   (United States)

^e YALE UNIVERSITY   (United States)

Author keywords

Analgesics; Chronic pain; Education; Medical; Naloxone; Opiate addiction; Opioid; Overdose; Rapid assessment and response

Indexed keywords

NALOXONE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ARTICLE; DRUG OVERDOSE; HEALTH PERSONNEL ATTITUDE; HUMAN; PRESCRIPTION; UNITED STATES;

ANALGESICS, OPIOID; ATTITUDE OF HEALTH PERSONNEL; DRUG OVERDOSE; DRUG PRESCRIPTIONS; HUMANS; NALOXONE; NARCOTIC ANTAGONISTS; NEW ENGLAND;

EID: 84877257167     PISSN: 10826084     EISSN: 15322491     Source Type: Journal    
DOI: 10.3109/10826084.2013.787099     Document Type: Article

References (46)

1. Albert, S., Brason Ii, F. W., Sanford, C. K., Dasgupta, N., Graham, J., & Lovette, B. (2011). Project Lazarus: Community-based overdose prevention in Rural North Carolina. Pain Medicine, 12, S77-S85.
2. American Medical Association. (2012). AMA adopts new policies at annual meeting. Retrieved September, 28, 2012, from http://www.ama-assn.org/ama/pub/ news/news/2012-06-19-ama-adopts-new-policies.page
3. Barreras, R. E., Drucker, E. M., & Rosenthal, D. (2005). The concentration of substance use, criminal justice involvement, and HIV/AIDS in the families of drug offenders. Journal of Urban Health, 82(1), 162-170.
4. Beletsky, L., Bell, A., Bowman, S., Burris, S., Dasgupta, N., Doe-Simkins, M., et al. (2012). Retrieved September 19, 2012, from www.prescribetoprevent.org
5. Beletsky, L., Ruthazer, R., Macalino, G. E., Rich, J. D., Tan, L., & Burris, S. (2007). Physicians' knowledge of and willingness to prescribe naloxone to reverse accidental opiate overdose: Challenges and opportunities. Journal of Urban Health, 84(1), 126-136.
6. Boyer, E. W. (2012). Management of opioid analgesic overdose. The New England Journal of Medicine, 367(2), 146-155.
7. Campbell, R. L., Luke, A., Weaver, A. L., St Sauver, J. L., Bergstralh, E. J., Li, J. T., et al. (2008). Prescriptions for self-injectable epinephrine and follow-up referral in emergency department patients presenting with anaphylaxis. Annals of Allergy, Asthma & Immunology, 101(6), 631-636.
8. Centers for Disease Control and Prevention (CDC). (2012). CDC grand rounds: Prescription drug overdoses-a U.S. epidemic. MMWR Morbidity and Mortality Weekly Report, 61(1) 10-13.
9. Centers for Disease Control and Prevention. (2010). QuickStats: Death rates for the three leading causes of injury death-United States 1979-2007. MMWR Morbidity and Mortality Weekly Report 59(30) 957.
10. Centers for Disease Control and Prevention. (2012b). Community-based opioid overdose prevention programs providing naloxone-United States, 2010. MMWR Morbidity and Mortality Weekly Report, 61(6), 101-105.
11. Centers for Disease Control and Prevention. (2012c). Vital Signs, Injury: The #3 killer of Children U.S. Retrieved October 15, 2012, from http://www.cdc.gov/vitalsigns/ChildInjury/infographic.html?s cid=bb-vitalsigns-124
12. Chelminski, P. R., Ives, T. J., Felix, K. M., Prakken, S. D., Miller, T. M., Perhac, J. S., et al. (2005). A primary care, multi-disciplinary disease management program for opioid-treated patients with chronic non-cancer pain and a high burden of psychiatric comorbidity. BMC Health Services Research Journal, 5(1), 3.
13. Clark, S., Bock, S. A., Gaeta, T. J., Brenner, B. E., Cydulka, R. K., & Camargo, C. A. (2004). Multicenter study of emergency department visits for food allergies. Journal of Allergy and Clinical Immunology, 113(2), 347-352.
14. Clark, S., Long, A. A., Gaeta, T. J., & Camargo, C. A., Jr. (2005). Multicenter study of emergency department visits for insect sting allergies. Journal of Allergy and Clinical Immunology, 116(3), 643-649.
15. Coffn, P. O., Fuller, C., Vadnai, L., Blaney, S., Galea, S., & Vlahov, D. (2003). Preliminary evidence of health care provider support for naloxone prescription as overdose fatality prevention strategy in New York City. Journal of Urban Health, 80(2), 288-290.
16. Dasgupta, N., Sanford, C., Albert, S., & Wells Brason, F. (2010). Opioid drug overdoses: A prescription for harm and potential for prevention. American Journal of Lifestyle Medicine, 4(1), 32-37.
17. Davis, C., & Chang, S. (2012). Legal interventions to reduce overdose mortality: Naloxone access and overdose Good Samaritan Laws. Retrieved October 15, 2012, from http://www.networkforphl.org/asset/qz5pvn/naloxone-FINAL.pdf
18. Doe-Simkins, M., Walley, A. Y., Epstein, A., & Moyer, P. (2009). Saved by the nose: Bystander-administered intranasal naloxone hydrochloride for opioid overdose. American Journal of Public Health, 99(5), 788-791.
19. Fenichel, R. R. (2004). Which drugs should be available over the counter? British Medical Journal, 329(7459), 182-183.
20. Gupta, R. S., Springston, E. E., Kim, J. S., Smith, B., Pongracic, J. A., Wang, X., et al. (2010). Food allergy knowledge, attitudes, and beliefs of primary care physicians. Pediatrics, 125(1), 126-132.
21. Heimer, R., Dasgupta, N., Irwin, K. S., Kinzly, M., Harvey, A. P., Givens, A., et al. (2012). Chronic pain, addiction severity, and misuse of opioids in Cumberland County, Maine. Addictive Behaviors, 37(3), 346-349.
22. Hurley, R. (2011). Pilot scheme shows that giving naloxone to families of drug users would save lives. British Medical Journal, 343. BMJ 2011;343:d5445. Retrieved November 1, 2011 from http://dx.doi.org/10.1136/bmj.d5445.
23. Kahan, M., Srivastava, A., Wilson, L., Gourlay, D., & Midmer, D. (2006). Misuse of and dependence on opioids: Study of chronic pain patients. Canadian Family Physician, 52(9), 1081-1087.
24. Kidorf, M., & King, V. L. (2008). Expanding the public health ben-efts of syringe exchange programs. Canadian Journal of Psychiatry, 53(8), 487-495.
25. Manchikanti, L., Abdi, S., Atluri, S., Balog, C. C., Benyamin, R. M., Boswell, M. V., et al. (2012). American Society of Interven-tional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2-guidance. Pain Physician, 15(3 Suppl), S67-S116.
26. Maxwell, S., Bigg, D., Stanczykiewicz, K., & Carlberg-Racich, S. (2006). Prescribing naloxone to actively injecting heroin users. Journal of Addictive Diseases, 25(3), 89-96.
27. Mayet, S., Manning, V., Williams, A., Loaring, J., & Strang, J. (2011). Impact of training for healthcare professionals on how to manage an opioid overdose with naloxone: Effective, but dissemination is challenging. International Journal of Drug Policy, 22(1), 9-15.
28. Mintzer, I. L., Eisenberg, M., Terra, M., MacVane, C., Himmelstein, D. U., & Woolhandler, S. (2007). Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. The Annals of Family Medicine, 5(2), 146-150.
29. Miotto, K., Hillhouse, M., Donovick, R., Cunningham-Rathner, J., Charuvastra, C., Torrington, M., et al. (2012). Comparison of buprenorphine treatment for opioid dependence in 3 settings. Journal of Addiction Medicine, 6(1), 68-76.
30. Paulozzi, L. J., Budnitz, D. S., & Xi, Y. (2006). Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Safety, 15(9), 618-627.
31. Peles, E., Schreiber, S., Gordon, J., & Adelson, M. (2005). Sig-nifcantly higher methadone dose for methadone maintenance treatment (MMT) patients with chronic pain. Pain, 113(3), 340-346.
32. Potter, J. S., Shiffman, S. J., & Weiss, R. D. (2008). Chronic pain severity in opioid-dependent patients. American Journal of Drug and Alcohol Abuse, 34(1), 101-107.
33. Raisch, D. W., Fye, C. L., Boardman, K. D., & Sather, M. R. (2002). Opioid dependence treatment, including buprenor-phine/naloxone. Annals of Pharmacotherapy, 36(2), 312-321.
34. Rosenblum, A., Joseph, H., Fong, C., Kipnis, S., Cleland, C., & Portenoy, R. K. (2003). Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. Journal of the American Medical Association, 289(18), 2370-2378.
35. Sampson, H. A., Munoz-Furlong, A., Campbell, R. L., Adkinson, N. F., Jr., Bock, S. A., Branum, A., et al. (2006). Second symposium on the defnition and management of anaphylaxis: Summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. Journal of Allergy and Clinical Immunology, 117(2), 391-397.
36. Savage, S. R., Kirsh, K. L., & Passik, S. D. (2008). Challenges in using opioids to treat pain in persons with substance use disorders. Addiction Science & Clinical Practice, 4(2), 4-25.
37. Schackman, B. R., Leff, J. A., Polsky, D., Moore, B. A., & Fiellin, D. A. (2012). Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care. Journal of General Internal Medicine, 27(6), 669-676.
38. Sentencing. 4th circuit: HIV diagnosis not valid excuse to violate probation. (2009). AIDS Policy Law, 24(2), 6.
39. Sheu, R., Lussier, D., Rosenblum, A., Fong, C., Portenoy, J., Joseph, H., et al. (2008). Prevalence and characteristics of chronic pain in patients admitted to an outpatient drug and alcohol treatment program. Pain Medicine, 9(7), 911-917.
40. Stimson, G. V., Donoghoe, M., Fitch, C., Rhodes, T. J., Ball, A., & Weiler, G. (2003). Rapid assessment and response technical guide. World Health Organization (Department of Child and Adolescent Health and Development, and Department of HIV/AIDS). Geneva, Switzerland.
41. Walley, A. (2011, November). Implementation and evaluation of Massachusetts' overdose education and naloxone distribution program. Paper presented at the APHA 139th Annual Meeting and Exposition, Washington DC.
42. Warner, M., Chen, L. H., & Makuc, D. M. (2009). Increase in fatal poisonings involving opioid analgesics in the United States, 1999-2006. NCHS Data Brief (22), 1-8.Hyattsville, MD: National Center for Health Statistics, 2009.
43. Yawn, B. P., & Fenton, M. J. (2012). Summary of the NIAID-sponsored food allergy guidelines. American Family Physician, 86(1), 43-50.
44. Yu, J. E., Kumar, A., Bruhn, C., Teuber, S. S., & Sicherer, S. H. (2008). Development of a food allergy education resource for primary care physicians. BMC Medical Education, 8, 45.
45. Zaller, N., Jeronimo, A., Bratberg, J., Case, P., & Rich, J. D. (2010). Pharmacist and pharmacy staff experiences with non-prescription (NP) sale of syringes and attitudes toward providing HIV prevention services for injection drug users (IDUs) in Providence, RI. Journal of Urban Health, 87(6), 942-953.
46. Zaller, N. D., Yokell, M. A., Green, T. C., Gaggin, J. W., & Case, P. (in press). The feasibility of pharmacy-based naloxone distribution interventions: a qualitative study with injection drug users and pharmacy staff in Rhode Island. Subst Use Misuse.